Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT04793958
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Interventions
Name:
MRTX849
Type:
DRUG
Description:
28 Day Cycle
Name:
Cetuximab
Type:
BIOLOGICAL
Description:
28 Day Cycle
Name:
mFOLFOX6 Regimen
Type:
DRUG
Description:
* Fluorouracil
* Oxaliplatin
* Folinic acid
Name:
FOLFIRI Regimen
Type:
DRUG
Description:
* Fluorouracil
* Irinotecan
* Folinic acid
Primary Outcomes
Measure:
Overall Survival (OS)
TimeFrame:
30 months
Description:
Defined as time from date of randomization to date of death due to any cause.
Measure:
Progression-free Survival (PFS)
TimeFrame:
30 months
Description:
Defined as time from randomization until disease progression or death from any cause, whichever occurs first.
Trial Information
NCT ID
NCT04793958
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Mirati Therapeutics Inc.
Last Updated
December 15, 2025